Gri Bio Inc. (GRI)

$0.51

+0.02

(+4.59%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.49
    $0.54
    $0.51
    downward going graph

    3.9%

    Downside

    Day's Volatility :9.22%

    Upside

    5.54%

    downward going graph
  • $0.40
    $161.98
    $0.51
    downward going graph

    21.53%

    Downside

    52 Weeks Volatility :99.75%

    Upside

    99.69%

    downward going graph

Returns

PeriodGri Bio Inc.Index (Russel 2000)
3 Months
-85.84%
0.0%
6 Months
-95.11%
0.0%
1 Year
-99.52%
0.0%
3 Years
-99.93%
-22.3%

Highlights

Market Capitalization
1.4M
Book Value
$5.89
Earnings Per Share (EPS)
57.07
PE Ratio
0.01
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-82.53%
Return On Equity TTM
-189.06%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-8.4M
Diluted Eps TTM
57.07
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Gri Bio Inc.(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Technicals Summary

Sell

Neutral

Buy

Gri Bio Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gri Bio Inc.
Gri Bio Inc.
11.41%
-95.11%
-99.52%
-99.93%
-99.99%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gri Bio Inc.
Gri Bio Inc.
0.01
0.01
NA
0.0
-1.89
-0.83
NA
5.89
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gri Bio Inc.
Gri Bio Inc.
Buy
$1.4M
-99.99%
0.01
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Gri Bio Inc.

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 136.6%

Company Information

gri is a development stage biotech company fundamentally changing the way inflammatory disease is treated. gri’s natural killer t (nkt) cell-based therapies are being developed for liver disease and acute liver failure. nkt cells share properties of both nk and t cells and are a functional link between the innate and adaptive immune responses. type 1 nkt cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. gri’s lead program, gri-0621, is an inhibitor of type i nkt cells and is being developed as a novel oral therapeutic for acute liver failure.

Organization
Gri Bio Inc.
Employees
4
CEO
Dr. W. Marc Hertz Ph.D.
Industry
Miscellaneous

Discover More

FAQs